Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low versus standard dose mCPP challenge in obsessive-compulsive patients.

S Erzegovesi1, L Martucci, M Henin

  • 1Department of Neuropsychiatric Sciences, S. Raffaele Hospital, University of Milan School of Medicine, Milano, Italy.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|December 7, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare Variant of Lateral Medullary Syndrome; Opalski Syndrome with Cerebellar Infarction.

Irish medical journal·2023
Same author

A proof-of-concept study applying machine learning methods to putative risk factors for eating disorders: results from the multi-centre European project on healthy eating.

Psychological medicine·2021
Same author

Giant duodenal polyp.

Acta gastro-enterologica Belgica·2021
Same author

Visuo-tactile shape perception in women with Anorexia Nervosa and healthy women with and without body concerns.

Neuropsychologia·2020
Same author

Rest-activity circadian rhythm and sleep quality in patients with binge eating disorder.

Chronobiology international·2017
Same author

Angiographic Anatomy of External Iliac Arteries in the Sheep.

Anatomia, histologia, embryologia·2015
Same journal

Auditory event-related potentials and psychosis dimensions.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Cultural humility in the teaching and practice of clinical care.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Kappa opioid receptors mediate aversion-and it matters.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Splice isoforms of the histone variant macroH2A1 differentially regulate hippocampal gene expression and memory formation.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Chronic ethanol self-administration alters dopamine in the caudate nucleus and putamen of rhesus macaques in a sex-dependent manner.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

In memoriam-Shigeto Yamawaki, M.D., Ph.D. (1954-2026).

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
See all related articles

A lower dose of meta-chlorophenylpiperazine (mCPP) specifically worsened obsessive-compulsive (OC) symptoms in half of patients, unlike the standard dose which showed minimal effects on anxiety.

Area of Science:

  • Neuroscience
  • Psychopharmacology
  • Clinical Psychology

Background:

  • Meta-chlorophenylpiperazine (mCPP), a partial serotonergic agonist, has been associated with worsening obsessive-compulsive (OC) symptoms at a 0.5 mg/kg dose.
  • Previous research on the 0.25 mg/kg mCPP dose was limited to healthy subjects, leaving its specific effects on OC patients uninvestigated.

Purpose of the Study:

  • To evaluate the efficacy of a lower dose (0.25 mg/kg) of mCPP in specifically targeting and potentially exacerbating OC symptoms.
  • To compare the effects of the low-dose mCPP against a standard dose (0.5 mg/kg) and placebo in OC patients.

Main Methods:

  • A double-blind, controlled crossover study involving 12 patients diagnosed with OC disorder.
  • Participants received oral administrations of 0.5 mg/kg mCPP, 0.25 mg/kg mCPP, or placebo on separate test days.

Related Experiment Videos

  • Behavioral symptom severity was assessed using Visual Analogue Scale (VAS) ratings.

    • Main Results:

    • The 0.25 mg/kg mCPP dose significantly worsened OC symptoms in 50% (6/12) of the patients.
    • In contrast, the standard 0.5 mg/kg mCPP dose led to symptom worsening in only 8.3% (1/12) of patients.
    • The standard dose showed a non-significant trend towards increased anxiety ratings, while the low dose had minimal anxiogenic effects.

    Conclusions:

    • The 0.25 mg/kg mCPP dose appears to elicit a specific worsening of OC symptoms with a reduced potential for inducing anxiety.
    • These preliminary findings suggest a potential therapeutic or diagnostic application for lower mCPP doses in OC disorder.
    • Further research with larger sample sizes and more sensitive rating scales is recommended to validate these results.